Title :

Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Author(s) :

Villar, Sara [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Chevret, Sylvie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Poire, Xavier [Auteur]
Joris, Magalie [Auteur]
CHU Amiens-Picardie
Chevallier, Patrice [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Bourhis, Jean-Henri [Auteur]
Institut Gustave Roussy [IGR]
Forcade, Edouard [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Chantepie, Sylvain [Auteur]
CHU Caen
Beauvais, David [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192
Raus, Nicole [Auteur]
Bay, Jacques-Olivier [Auteur]
CHU Estaing [Clermont-Ferrand]
Loschi, Michael [Auteur]
Université Côte d'Azur [UniCA]
Devillier, Raynier [Auteur]
Institut Paoli-Calmettes [IPC]
Duléry, Remy [Auteur]
Sorbonne Université [SU]
Ceballos, Patrice [Auteur]
CHU Montpellier = Montpellier University Hospital
Rubio, Marie-Therese [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Servais, Sophie [Auteur]
Université de Liège = University of Liège = Universiteit van Luik = Universität Lüttich [ULiège]
Nguyen, Stephanie [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Robin, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]

Journal title :

Bone Marrow Transplantation

Abbreviated title :

Bone Marrow Transplant

Volume number :

59

Pages :

965–973

Publication date :

2024-07

ISSN :

1476-5365

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

In this SFGM-TC registry study, we report the results after stem cell transplantation (HSCT) in 305 myelofibrosis patients, in order to determine potential risk factors associated with outcomes, especially regarding previous ...
Show more >In this SFGM-TC registry study, we report the results after stem cell transplantation (HSCT) in 305 myelofibrosis patients, in order to determine potential risk factors associated with outcomes, especially regarding previous treatment with ruxolitinib. A total of 102 patients were transplanted from an HLA-matched-sibling donor (MSD), and 143 patients received ruxolitinib. In contrast with previous studies, our results showed significantly worse outcomes for ruxolitinib patients regarding overall survival (OS) and non-relapse mortality (NRM), especially in the context of unrelated donors (URD). When exploring reasons for potential confounders regarding the ruxolitinib effect, an interaction between the type of donor and the use of ATG was found, therefore subsequent analyses were performed separately for each type of donor. Multivariable analyses did not confirm a significant negative impact of ruxolitinib in transplantation outcomes. In the setting of URD, only age and Fludarabine-Melphalan (FM) conditioning were associated with increased NRM. For MSD, only Karnoksfy <70% was associated with reduced OS. However, a propensity score analysis showed that ruxolitinib had a negative impact on OS but only in non-responding patients, consistent with previous data. To conclude, with all the precautions due to confounders and bias, ruxolitinib itself does not appear to increase mortality after HSCT.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U1192

Submission date :

2024-05-06T21:32:40Z
2024-09-05T13:23:49Z